New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
19:09 EDTDRTX, MDR, MDCO, AMRN, VRNT, ARTX, CBSTOn The Fly: After Hours Movers
HIGHER: Durata Therapeutics (DRTX), up 5.4% after an FDA Committee voted in favor of its Dalvance injection for the treatment of adult patients with acute bacterial skin and skin structure infections caused by certain bacteria... Amarin (AMRN), up 8.8% after announcing a co-promotion agreement with Kowa Pharmaceuticals America for its Vascepa capsules in the U.S... Verint Systems (VRNT), up 10% after reporting earnings that beat expectations and providing a fiscal year outlook that also topped estimates. LOWER: The Medicines Company (MDCO), down 14.3% after Durata and Cubist Pharmaceuticals (CBST) each received positive votes from FDA panels for bacteria treatments that could compete with its Oritavancin. Cubist (CBST), which confirmed the FDA panel vote intraday, saw shares gain $3.05, or 4.35%, to close at $73.15 for the session... Arotech (ARTX), down 12.5% after reporting fiscal year earnings and revenue that disappointed... McDermott (MDR), down 2.8% after filing to sell 10M tangible equity units and, in a separate release, saying that its first quarter results may differ "substantially" from the company's current expectation.
News For DRTX;MDR;MDCO;AMRN;VRNT;ARTX;CBST From The Last 14 Days
Check below for free stories on DRTX;MDR;MDCO;AMRN;VRNT;ARTX;CBST the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
05:33 EDTCBSTCubist opens international headquarters in Zurich, will invest $400M in R&D
Subscribe for More Information
September 16, 2014
05:59 EDTAMRNAmarin to host conference call
Conference call to discuss its commitment to the REDUCE-IT study will be held on September 16 at 8 am. Webcast Link
05:34 EDTAMRNAmarin commits to completing REDUCE-IT cardiovascular outcomes study
Subscribe for More Information
September 15, 2014
07:02 EDTMDRMcDermott completes contract scope for Jack, St. Malo project
Subscribe for More Information
September 12, 2014
16:20 EDTAMRNOn The Fly: Closing Wrap
Subscribe for More Information
14:59 EDTAMRNAmarin weakness an overreaction, says Citigroup
Subscribe for More Information
12:51 EDTAMRNOn The Fly: Midday Wrap
Stocks on Wall Street opened in negative territory and have remained there throughout the morning. The days economic data, including retail sales figures, a report on import prices, and business inventories data, were generally in line with expectations. The economic bright spot was the University of Michigan consumer confidence report which came in higher than expected. The market is on the verge of ending the week lower, which would be its first weekly loss in the last seven. ECONOMIC EVENTS: In the U.S., sales at retailers climbed 0.6% in August, matching expectations but also representing the fastest pace in four months. Retail sales growth for July was also revised upward to 0.3% from a prior estimate of having been flat. Import prices dropped 0.9% in August, while export prices slipped 0.5%. The University of Michigan preliminary consumer sentiment reading for for September rose to 84.6, beating expectations for it to be up more modestly to 83.3. Business inventories grew 0.4% in July, as expected. COMPANY NEWS: Shares of eBay (EBAY) were up more than 2% near noon after rumors circulated that Google (GOOG) may look to take a stake in the company. However, an eBay spokesperson denied the speculation, telling Reuters that the company has held "no conversations" with Google about acquiring a stake. MAJOR MOVERS: Among the notable gainers was digital marketing services company Conversant (CNVR), which soared 30% after Alliance Data Systems (ADS) agreed to acquire it for about $2.3B in cash and stock. Following last night's announcement of the deal, some Conversant peers rose as well, as Criteo (CRTO) gained almost 5% and TubeMogul (TUBE) rose 1%, while Alliance Data gained over 2%. Among the noteworthy losers was Amarin (AMRN), which dropped 22% after an office within the FDA denied the company's appeal of FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment agreement. Also lower were shares of Ruckus Wireless (RKUS), which fell 5% after one analyst downgraded the shares and another initiated coverage of the stock with an Underweight rating. INDEXES: Near midday, the Dow was down 66.43, or 0.39%, to 16,982.57, the Nasdaq was down 19.83, or 0.43%, to 4,571.97, and the S&P 500 was down 10.28, or 0.51%, to 1,987.17.
12:12 EDTMDCOThe Medicines Co. to host conference call
Subscribe for More Information
10:10 EDTAMRNHigh option volume stocks
Subscribe for More Information
09:14 EDTAMRNOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTAMRNAmarin down 24.3% after FDA office denies appeal of ANCHOR rescission
09:03 EDTAMRNAmarin says FDA office denies appeal of ANCHOR rescission
Subscribe for More Information
09:02 EDTAMRNAmarin says FDA office denies appeal of ANCHOR rescission
September 10, 2014
14:17 EDTAMRNAmarin says Vascepa SPA rescission appeal on ANCHOR sNDA ongoing
Amarin says it is appealing to a higher level and if appeal is not successful that the company may pursue judicial relief under the First Amendment. Amarin says that the fight over Vascepa's sNDA for a mixed dyslipidemia indication is an "uphill battle," but the company believes patient care would benefit and that the company has valid legal, clinical and regulatory arguments. Information from slides for the company's presentation at the Rodman & Renshaw Global Investment conference.
September 9, 2014
08:59 EDTMDRDA Davidson's construction analyst holds an analyst/industry conference call
Subscribe for More Information
September 5, 2014
12:57 EDTVRNTOn The Fly: Midday Wrap
Subscribe for More Information
07:29 EDTDRTXDurata Therapeutics management to meet with Summer Street
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use